Factors associated with virological failure in a cohort of combination antiretroviral therapy-treated patients managed at a tertiary referral centre

Sexual Health

Volumn 10, Issue 5, 2013, Pages 442-447

  Fong, Raymond ^a,c   Cheng, Allen C ^a,b   Vujovic, Olga ^a,b   Hoy, Jennifer F ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

adherence; HIV; treatment failure

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COMBINATION ANTIRETROVIRAL THERAPY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; TREATMENT FAILURE; VIROLOGICAL FAILURE;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; COINFECTION; COMORBIDITY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT FAILURE; VICTORIA; VIRAL LOAD; YOUNG ADULT;

EID: 84886894543     PISSN: 14485028     EISSN: 14498987     Source Type: Journal    
DOI: 10.1071/SH13043     Document Type: Article

References (39)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338(13): 853-60. doi:10.1056/NEJM199803263381301
2. Spacek LA, Shihab HM, Kamya MR, Mwesigire D, Ronald A, Mayanja H, et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis 2006; 42(2): 252-9. doi:10.1086/499044
3. Boileau C, Nguyen VK, Sylla M, Machouf N, Chamberland A, Traore HA, et al. Low prevalence of detectable HIV plasma viremia in patients treated with antiretroviral therapy in Burkina Faso and Mali. J Acquir Immune Defic Syndr 2008; 48(4): 476-84. doi:10.1097/QAI.0b013e31817dc416
4. Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr 2005; 40(3): 324-8. doi:10.1097/01. qai.0000182627.28595.01
5. Zaccarelli M, Tozzi V, Lorenzini P, Trotta MP, Forbici F, Visco-Comandini U, et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients. AIDS 2005; 19(10): 1081-9. doi:10.1097/01.aids. 0000174455.01369.ad
6. Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004; 364(9428): 51-62. doi:10.1016/S0140- 6736(04)16589-6
7. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009; 49(10): 1582-90. doi:10.1086/644768
8. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007; 36(2): 294-301. doi:10.1093/ije/dyl286
9. Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166(5): 521-8. doi:10.1001/archinte. 166.5.521
10. Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, et al. Predicting virologic failure in an HIV clinic. Clin Infect Dis 2010; 50(5): 779-86.
11. Taylor-Castillo L, Herrera-Martinez G, Leon-Bratti MP, Boza R, Leon-Rodriguez B, Luftig RB, et al. Study of antiretroviral mutants in HIV patients with treatment failures and the effect of risk factors in the virological failures. Rev Inst Med Trop Sao Paulo 2005; 47(6): 327-31. doi:10.1590/S0036-46652005000 600004
12. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, Larouze B, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38(9): 1311-6. doi:10.1086/383572
13. Knobel H, Guelar A, Carmona A, Espona M, Gonzalez A, Lopez-Colomes JL, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDS 2001; 15(4): 193-9. doi:10.1089/10872910151133729
14. Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160(8): 1123-32. doi:10.1001/archinte.160. 8.1123
15. Míguez MJ, Lewis JE, Bryant VE, Rosenberg R, Burbano X, Fishman J, et al. Low cholesterol? Don't brag yet. hypocholesterolemia blunts HAART effectiveness: a longitudinal study. J Int AIDS Soc 2010; 13: 25. doi:10.1186/1758-2652-13-25
16. Ahoua L, Guenther G, Pinoges L, Anguzu P, Chaix ML, Le Tiec C, et al. Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. BMC Infect Dis 2009; 9: 81. doi:10.1186/1471-2334-9-81
17. Tsuchiya N, Pathipvanich P, Yasuda T, Mukoyama Y, Rojanawiwat A, Matsubayashi T, et al. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. Southeast Asian J Trop Med Public Health 2009; 40(1): 71-82.
18. Robbins GK, Daniels B, Zheng H, Chueh H, Meigs JB, Freedberg KA. Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr 2007; 44(1): 30-7. doi:10.1097/01. qai.0000248351.10383.b7
19. Aitchison SJ, Watson KM, McCartney LM, Matthew R, Hoy J, eds. HIV Demographics in a single clinic: continued room for improvement. Australasian HIV/AIDS Conference; 2012 October 17-19; Melbourne, Australia. Sydney: Australasian Society for HIV Medicine.
20. Bloch M, Farris M, Tilden D, Gowers A, Cunningham N. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting. Sex Health 2010; 7(1): 17-24. doi:10.1071/SH09039
21. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010; 50(2): 264-71. doi:10.1086/649215
22. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003; 17: S5-15. doi:10.1097/00002030-200317003-00002
23. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007; 45(1): 52-9. doi:10.1097/QAI.0b013e318042e1c3
24. Fielding KL, Charalambous S, Stenson AL, Pemba LF, Martin DJ, Wood R, et al. Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. BMC Infect Dis 2008; 8: 93. doi:10.1186/1471-2334-8-93
25. Bedelu M, Ford N, Hilderbrand K, Reuter H. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 2007; 196: S464-8. doi:10.1086/521114
26. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31: S103-6. doi:10.1097/00126334-200212153-00003
27. Hecht FM. Measuring HIV treatment adherence in clinical practice. AIDS Clin Care 1998; 10(8): 57-9.
28. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006; 43: S79-87. doi:10.1097/01.qai.0000248337.97814.66
29. Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JH, Raper JL, et al. Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr 2009; 50(1): 100-8. doi:10.1097/QAI.0b013e31818d5c37
30. Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999; 11(3): 361-73. doi:10.1080/09540129947983
31. Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007; 44(11): 1493-9. doi:10.1086/516778
32. Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Routman JS, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48(2): 248-56. doi:10.1086/595705
33. Pulido F, Hill A, van Delft Y, Moecklinghoff C. Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev 2012; 14(2): 124-31.
34. Ballif M, Ledergerber B, Battegay M, Cavassini M, Bernasconi E, Schmid P, et al. Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE 2009; 4(12): e8275. doi:10.1371/journal.pone.0008275
35. Grimes RM, Otiniano ME, Rodriguez-Barradas MC, Lai D. Clinical experience with human immunodeficiency virus-infected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 2002; 34(11): 1530-3. doi:10.1086/340404
36. Miller LG, Liu H, Hays RD, Golin CE, Beck CK, Asch SM, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002; 17(1): 1-11. doi:10.1046/j.1525-1497.2002.09004.x
37. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360(9327): 119-29. doi:10.1016/S0140-6736 (02)09411-4
38. Tumbarello M, Rabagliati R, de Gaetano Donati K, Bertagnolio S, Montuori E, Tamburrini E, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4: 46. doi:10.1186/1471-2334-4-46
39. Mayer KH. Introduction: linkage, engagement, and retention in HIV care: essential for optimal individual-and community-level outcomes in the era of highly active antiretroviral therapy. Clin Infect Dis 2011; 52: S205-7. doi:10.1093/cid/ciq043